secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2021-08-02T23:59:59+00:00
Accession:  0001171843-21-005373
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q2 net loss $11.8M; discontinues COVID-19 trial, cuts cash burn guidance
-------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $66.5M at June 30, 2021, up from $44.3M at Dec 31, 2020.
- Net loss $11.8M for Q2 2021 vs $10.6M in Q2 2020; R&D expenses $9.1M (up $1.2M YoY).
- Discontinued Phase 3 mupadolimab COVID-19 trial in July 2021 (no safety/efficacy issue); full-year cash burn guidance cut ~$11M to $35-37M.
- Enrolling Phase 1b/2 trial of mupadolimab plus pembrolizumab in HPV+ oropharyngeal cancer; results expected by year-end 2021.
- Angel Pharmaceuticals filed IND in China for CPI-818 Phase 2 in T-cell lymphomas; ciforadenant Phase 2 RCC trial planned with Kidney Cancer Consortium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/0001171843-21-005373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/f8k_080221.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer